JP7584535B2 - アリピプラゾール注射用調製物を投与する方法 - Google Patents

アリピプラゾール注射用調製物を投与する方法 Download PDF

Info

Publication number
JP7584535B2
JP7584535B2 JP2022559751A JP2022559751A JP7584535B2 JP 7584535 B2 JP7584535 B2 JP 7584535B2 JP 2022559751 A JP2022559751 A JP 2022559751A JP 2022559751 A JP2022559751 A JP 2022559751A JP 7584535 B2 JP7584535 B2 JP 7584535B2
Authority
JP
Japan
Prior art keywords
aripiprazole
injectable preparation
patient
salt
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519425A (ja
Inventor
ハーリン，マシュー
ワン，シャオフォン
ワン，ヤンリン
ラウフィニア，アラシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7584535(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of JP2023519425A publication Critical patent/JP2023519425A/ja
Priority to JP2024193628A priority Critical patent/JP2025020306A/ja
Application granted granted Critical
Publication of JP7584535B2 publication Critical patent/JP7584535B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
JP2022559751A 2020-04-01 2021-04-01 アリピプラゾール注射用調製物を投与する方法 Active JP7584535B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024193628A JP2025020306A (ja) 2020-04-01 2024-11-05 アリピプラゾール注射用調製物を投与する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
US63/003,544 2020-04-01
PCT/JP2021/014192 WO2021201238A1 (en) 2020-04-01 2021-04-01 Methods of administering an aripiprazole injectable preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024193628A Division JP2025020306A (ja) 2020-04-01 2024-11-05 アリピプラゾール注射用調製物を投与する方法

Publications (2)

Publication Number Publication Date
JP2023519425A JP2023519425A (ja) 2023-05-10
JP7584535B2 true JP7584535B2 (ja) 2024-11-15

Family

ID=75581573

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022559751A Active JP7584535B2 (ja) 2020-04-01 2021-04-01 アリピプラゾール注射用調製物を投与する方法
JP2022559750A Active JP7733000B2 (ja) 2020-04-01 2021-04-01 アリピプラゾール治療の投薬開始のための方法
JP2024193628A Pending JP2025020306A (ja) 2020-04-01 2024-11-05 アリピプラゾール注射用調製物を投与する方法
JP2025137577A Pending JP2025176037A (ja) 2020-04-01 2025-08-21 アリピプラゾール治療の投薬開始のための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022559750A Active JP7733000B2 (ja) 2020-04-01 2021-04-01 アリピプラゾール治療の投薬開始のための方法
JP2024193628A Pending JP2025020306A (ja) 2020-04-01 2024-11-05 アリピプラゾール注射用調製物を投与する方法
JP2025137577A Pending JP2025176037A (ja) 2020-04-01 2025-08-21 アリピプラゾール治療の投薬開始のための方法

Country Status (16)

Country Link
US (5) US20220160621A1 (https=)
EP (3) EP4125903B1 (https=)
JP (4) JP7584535B2 (https=)
KR (3) KR102732030B1 (https=)
CN (3) CN115397420A (https=)
AU (2) AU2021245713A1 (https=)
BR (2) BR112022018647A2 (https=)
CA (3) CA3136727A1 (https=)
ES (1) ES2995466T3 (https=)
HR (1) HRP20241574T1 (https=)
HU (1) HUE069157T2 (https=)
MX (2) MX2022012353A (https=)
PL (1) PL4125903T3 (https=)
TW (3) TWI865760B (https=)
WO (2) WO2021201238A1 (https=)
ZA (1) ZA202210633B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI865760B (zh) 2020-04-01 2024-12-11 日商大塚製藥股份有限公司 阿立哌唑注射用製劑之投予方法
US20250387321A1 (en) 2023-03-17 2025-12-25 Otsuka Pharmaceutical Co., Ltd. Methods of dispersing aripiprazole injectable preparations
AU2024263986A1 (en) * 2023-04-26 2025-10-09 Otsuka Pharmaceutical Co., Ltd. Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4836797B2 (ja) 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
JP2015514751A (ja) 2012-04-23 2015-05-21 大塚製薬株式会社 注射製剤
US20190076425A1 (en) 2017-05-16 2019-03-14 Bow River LLC Methods of treatment with cyp3a4 substrate drugs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
MX2009014115A (es) 2007-06-25 2010-04-21 Otsuka Pharma Co Ltd Microesferas que tienen estructura de nucleo/corteza.
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
EP3761983A1 (en) * 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
TWI865760B (zh) 2020-04-01 2024-12-11 日商大塚製藥股份有限公司 阿立哌唑注射用製劑之投予方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4836797B2 (ja) 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
JP2015514751A (ja) 2012-04-23 2015-05-21 大塚製薬株式会社 注射製剤
US20190076425A1 (en) 2017-05-16 2019-03-14 Bow River LLC Methods of treatment with cyp3a4 substrate drugs

Also Published As

Publication number Publication date
KR20220161403A (ko) 2022-12-06
HRP20241574T1 (hr) 2025-01-31
EP3941470A1 (en) 2022-01-26
CN119792290A (zh) 2025-04-11
TW202200141A (zh) 2022-01-01
EP4467194A3 (en) 2025-01-08
US20240374506A1 (en) 2024-11-14
TW202200142A (zh) 2022-01-01
ZA202210633B (en) 2025-01-29
JP7733000B2 (ja) 2025-09-02
MX2022012353A (es) 2022-10-31
JP2023520004A (ja) 2023-05-15
AU2021248212A1 (en) 2022-12-01
KR20240165486A (ko) 2024-11-22
WO2021201239A1 (en) 2021-10-07
KR20220161402A (ko) 2022-12-06
KR102732030B1 (ko) 2024-11-20
US20260034053A1 (en) 2026-02-05
AU2021245713A1 (en) 2022-12-01
MX2022012354A (es) 2022-10-31
US20230129919A1 (en) 2023-04-27
US20220160621A1 (en) 2022-05-26
CN115379842A (zh) 2022-11-22
BR112022018647A2 (pt) 2022-11-08
HUE069157T2 (hu) 2025-02-28
CA3136727A1 (en) 2021-10-07
JP2025020306A (ja) 2025-02-12
CA3163321A1 (en) 2021-10-07
BR112022018721A2 (pt) 2022-11-01
EP4125903B1 (en) 2024-10-09
EP4125903A1 (en) 2023-02-08
EP4467194A2 (en) 2024-11-27
TWI865760B (zh) 2024-12-11
TW202523329A (zh) 2025-06-16
WO2021201238A1 (en) 2021-10-07
EP4125903C0 (en) 2024-10-09
US20230225962A1 (en) 2023-07-20
CN115397420A (zh) 2022-11-25
CA3163321C (en) 2023-12-19
JP2023519425A (ja) 2023-05-10
JP2025176037A (ja) 2025-12-03
PL4125903T3 (pl) 2025-02-03
ES2995466T3 (en) 2025-02-10
TWI906279B (zh) 2025-12-01
CA3212191A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
JP7584535B2 (ja) アリピプラゾール注射用調製物を投与する方法
US9782403B2 (en) Treating sexual desire disorders with flibanserin
JP4542743B2 (ja) ピリドン誘導体の溶液状医薬組成物
EP3785698B1 (en) Edaravone pharmaceutical composition
CA2961528A1 (en) Long acting pharmaceutical compositions
JP3792251B2 (ja) 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用
US20260115131A1 (en) Methods of administering an aripiprazole injectable preparation
NZ796242A (en) Rescue treatment of post operative nausea and vomiting
HK40077871A (en) Methods of administering an aripiprazole injectable preparation
EP4647082A1 (en) Pharmaceutical composition comprising a cgrp receptor antagonist for the treatment of acute migraine
JP2004528315A (ja) 予備混合アミオダロンの非経口溶液および同溶液を作製するための方法
HK40120297A (en) Methods for dose initiation of aripiprazole treatments
WO2025202938A1 (en) Pharmaceutical composition comprising a cgrp receptor antagonist for the treatment of acute migraine
HK40081123A (en) Methods for dose initiation of aripiprazole treatments
HK40081123B (en) Methods for dose initiation of aripiprazole treatments
HK40063844B (zh) 一种药物组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241105

R150 Certificate of patent or registration of utility model

Ref document number: 7584535

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150